Legend: CC = Colorado Convention Center H = Hyatt Regency Denver at Colorado Convention Center
Activity Details
172
Mon, 7/29/2019,
10:30 AM -
12:20 PM
CC-109
Quantitative Decision Making in Clinical Trials — Contributed Papers
Biopharmaceutical Section
Chair(s): Xiao Fang, Merck
10:35 AM
Defensive Efficacy Interim Design: Dynamic Benefit/Risk Ratio View Using Probability of Success
Zhongwen Tang, Abbvie
10:50 AM
In Silico Clinical Trials : a Way to Improve Clinical Development?
Nicolas SAVY, Toulouse Institute of Mathematics ; Philippe SAINT-PIERRE, Toulouse Institute of Mathematics ; Stephanie SAVY, ESTRIALS; Emmanuel PHAM, IPSEN Innovation SAS
11:05 AM
Single-Arm Two- and Three-Stage Phase 2 Clinical Trials with Go/No-Go/Inconclusive Outcomes with Handling of Overrunning/Under-Running
Bob Zhong, Johnson and Johnson ; Wenchuan Guo, Bristol-Myers Squibb Company; Jianan Hui, Boehringer Ingelheim Pharmaceuticals Inc.
11:20 AM
Quantitative Decision-Making for Single Arm POC Studies in Early Phase Oncology
Zhuqing Tina Liu, Eli Lilly and Company ; Jingyi Liu, Eli Lilly and Company
11:35 AM
Quantitative Decision Making in Early Clinical Development – Some Statistical Considerations
Weidong Zhang, Pfizer
11:50 AM
Bayesian Interim Prediction of Probability of Clinical Trial Success
Ying Grace Li, Eli Lilly and Company
12:05 PM
Infusing Bayesian Strategies for Pharmaceutical Manufacturing and Development
Bill Pikounis, Johnson & Johnson ; Dwaine Banton, Janssen R&D; John Oleynick, Johnson & Johnson; Jyh-Ming Shoung, Janssen R&D
